John Harris to Janus Kinase 1
This is a "connection" page, showing publications John Harris has written about Janus Kinase 1.
Connection Strength
0.348
-
Tang Q, Fakih HH, Zain Ui Abideen M, Hildebrand SR, Afshari K, Gross KY, Sousa J, Maebius AS, Bartholdy C, S?gaard PP, Jackerott M, Hariharan V, Summers A, Fan X, Okamura K, Monopoli KR, Cooper DA, Echeverria D, Bramato B, McHugh N, Furgal RC, Dresser K, Winter SJ, Biscans A, Chuprin J, Haddadi NS, Sherman S, Yildiz-Altay ?, Rashighi M, Richmond JM, Bouix-Peter C, Blanchard C, Clauss A, Alterman JF, Khvorova A, Harris JE. Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nat Commun. 2023 11 04; 14(1):7099.
Score: 0.206
-
Fakih HH, Zain Ui Abideen M, Rachid MO, Gross KY, Ormsby TJR, Ross VM, Gagnon R, Dahlke C, Furgal RC, Lochmann C, Summers A, Sleiman HF, F?rst SM, Jackson SN, Gordilho JO, Bouix-Peter C, Portal T, Tang Q, Harris JE, Khvorova A, Blanchard C, Alterman JF. Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model. Nat Commun. 2026 Feb 03; 17(1).
Score: 0.060
-
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 10 20; 387(16):1445-1455.
Score: 0.048
-
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.
Score: 0.034